Myokardia (NASDAQ:MYOK) had its price target hoisted by BMO Capital Markets from $65.00 to $83.00 in a research note issued to investors on Friday. BMO Capital Markets currently has an outperform rating on the biotechnology company’s stock.
MYOK has been the topic of several other research reports. Credit Suisse Group reissued an outperform rating and issued a $60.00 price target on shares of Myokardia in a report on Thursday, January 18th. ValuEngine downgraded Myokardia from a hold rating to a sell rating in a report on Friday, December 1st. Wedbush raised their price target on Myokardia from $51.00 to $69.00 and gave the stock an outperform rating in a report on Friday. BidaskClub raised Myokardia from a sell rating to a hold rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research downgraded Myokardia from a hold rating to a sell rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. Myokardia presently has an average rating of Buy and a consensus target price of $63.00.
Myokardia (NASDAQ:MYOK) opened at $51.00 on Friday. Myokardia has a 1-year low of $10.80 and a 1-year high of $62.83. The company has a market capitalization of $1,905.75, a P/E ratio of -36.17 and a beta of 3.35.
In other Myokardia news, insider Jake Bauer sold 5,000 shares of Myokardia stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $42.89, for a total transaction of $214,450.00. Following the sale, the insider now owns 62,877 shares of the company’s stock, valued at approximately $2,696,794.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Anastasios Gianakakos sold 3,000 shares of Myokardia stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $41.09, for a total value of $123,270.00. Following the sale, the insider now directly owns 512,117 shares in the company, valued at approximately $21,042,887.53. The disclosure for this sale can be found here. In the last three months, insiders sold 848,326 shares of company stock worth $35,859,872. Company insiders own 33.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in MYOK. Wells Fargo & Company MN raised its stake in Myokardia by 2.5% during the 2nd quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 455 shares in the last quarter. Alliancebernstein L.P. bought a new stake in Myokardia during the 2nd quarter valued at $148,000. Teachers Advisors LLC raised its stake in Myokardia by 40.0% during the 2nd quarter. Teachers Advisors LLC now owns 30,667 shares of the biotechnology company’s stock valued at $402,000 after acquiring an additional 8,766 shares in the last quarter. Nationwide Fund Advisors raised its stake in Myokardia by 36.3% during the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 2,591 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in Myokardia by 61.6% during the 2nd quarter. New York State Common Retirement Fund now owns 18,893 shares of the biotechnology company’s stock valued at $247,000 after acquiring an additional 7,199 shares in the last quarter. 83.91% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Myokardia (MYOK) Price Target Raised to $83.00 at BMO Capital Markets” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3258532/myokardia-myok-price-target-raised-to-83-00-at-bmo-capital-markets.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.